Fluoropharma Medical Inc (FPMI) 0.2400 $FPMI
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016
Marketwired - Fri Jun 17, 1:07PM CDT
MONTCLAIR, NJ--(Marketwired - June 17, 2016) - FluoroPharma Medical, Inc. (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:30 p.m. EDT on Wednesday, June 22, 2016. The objectives of the call are to provide updates on recent company news and address questions from investors.
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals
Marketwire Canada - Thu Jun 09, 11:31AM CDT
MONTCLAIR, NJ--(Marketwired - June 09, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has entered into a nonbinding letter of intent with Ground Fluor Pharmaceuticals, Inc. (GFP) to acquire GFP.
FLR: 53.53 (+0.80)
FluoroPharma Enters Development and Commercialization Agreement for China and Canada
Marketwired - Mon Jun 06, 8:51AM CDT
MONTCLAIR, NJ--(Marketwired - June 06, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma's proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.
FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific Meeting of the American Society of Nuclear Cardiology
Marketwire Canada - Wed May 25, 8:39AM CDT
MONTCLAIR, NJ--(Marketwired - May 25, 2016) - FluoroPharma Medical Inc., (OTCQB: FPMI) today announced the acceptance of the first comparative data from it's Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease (CAD). The abstract was accepted for oral presentation on September 24th, 2016 in Boca Raton, Florida.
FluoroPharma Medical Announces Details for Investor Call on January 6th
Marketwired - Tue Jan 05, 11:20AM CST
FluoroPharma Medical Inc., (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:00 p.m. EST on Wednesday, January 6, 2016. The objectives of the call are to introduce Thomas H. Tulip, Ph.D., the company's new President and Chief Executive Officer, share his vision for the company, and address questions from investors.
FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer
Marketwired - Tue Dec 29, 3:32PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today the appointment of Dr. Thomas Tulip, PhD as Chief Executive Officer.
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves
Marketwired - Fri Oct 23, 6:52AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of cardiovascular disease, announced today the release of a company overview as presented by FluoroPharma's Chairman & CEO, Thijs Spoor, and its President, Thomas Tulip, PhD.
Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc.
Marketwired - Tue Oct 06, 9:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Dr. Thomas H. Tulip will join the company as President and will be responsible for the Company's day-to-day operations, with a focus on global product and business development strategies.
FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh Annual Equity Conference January 21, 2015
Marketwired - Fri Jan 16, 4:08PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that its VP Marketing, Ed Lyons, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday January 21st at 9:30am Eastern Standard Time.
FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD)
Marketwired - Thu Dec 04, 10:00AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that enrollment for this Phase II trial will be closing on December 15th . To date, FluoroPharma believes it has acquired sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.
Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study Suggest FluoroPharma's CardioPET Has a Promising Role for the Identification of Functionally Significant Coronary Artery Disease
Marketwired - Mon Nov 03, 7:55AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced an online publication in the Journal of Nuclear Cardiology on October 25, 2014 titled "A New F-18 Labeled PET Tracer For Fatty Acid Imaging."
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden
Marketwired - Mon Oct 20, 7:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented by Dr. Fabian Demeure, an author of the abstract, at the session: Cardiovascular System: Cardiac PET Imaging on October 19th at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016
Marketwired - Fri Jun 17, 1:07PM CDT
MONTCLAIR, NJ--(Marketwired - June 17, 2016) - FluoroPharma Medical, Inc. (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:30 p.m. EDT on Wednesday, June 22, 2016. The objectives of the call are to provide updates on recent company news and address questions from investors.
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals
Marketwire Canada - Thu Jun 09, 11:31AM CDT
MONTCLAIR, NJ--(Marketwired - June 09, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has entered into a nonbinding letter of intent with Ground Fluor Pharmaceuticals, Inc. (GFP) to acquire GFP.
FLR: 53.53 (+0.80)
FluoroPharma Enters Development and Commercialization Agreement for China and Canada
Marketwired - Mon Jun 06, 8:51AM CDT
MONTCLAIR, NJ--(Marketwired - June 06, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma's proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.
FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific Meeting of the American Society of Nuclear Cardiology
Marketwire Canada - Wed May 25, 8:39AM CDT
MONTCLAIR, NJ--(Marketwired - May 25, 2016) - FluoroPharma Medical Inc., (OTCQB: FPMI) today announced the acceptance of the first comparative data from it's Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease (CAD). The abstract was accepted for oral presentation on September 24th, 2016 in Boca Raton, Florida.
FluoroPharma Medical Announces Details for Investor Call on January 6th
Marketwired - Tue Jan 05, 11:20AM CST
FluoroPharma Medical Inc., (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:00 p.m. EST on Wednesday, January 6, 2016. The objectives of the call are to introduce Thomas H. Tulip, Ph.D., the company's new President and Chief Executive Officer, share his vision for the company, and address questions from investors.
FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer
Marketwired - Tue Dec 29, 3:32PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today the appointment of Dr. Thomas Tulip, PhD as Chief Executive Officer.
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves
Marketwired - Fri Oct 23, 6:52AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of cardiovascular disease, announced today the release of a company overview as presented by FluoroPharma's Chairman & CEO, Thijs Spoor, and its President, Thomas Tulip, PhD.
Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc.
Marketwired - Tue Oct 06, 9:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Dr. Thomas H. Tulip will join the company as President and will be responsible for the Company's day-to-day operations, with a focus on global product and business development strategies.
FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh Annual Equity Conference January 21, 2015
Marketwired - Fri Jan 16, 4:08PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that its VP Marketing, Ed Lyons, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday January 21st at 9:30am Eastern Standard Time.
FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD)
Marketwired - Thu Dec 04, 10:00AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that enrollment for this Phase II trial will be closing on December 15th . To date, FluoroPharma believes it has acquired sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.
Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study Suggest FluoroPharma's CardioPET Has a Promising Role for the Identification of Functionally Significant Coronary Artery Disease
Marketwired - Mon Nov 03, 7:55AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced an online publication in the Journal of Nuclear Cardiology on October 25, 2014 titled "A New F-18 Labeled PET Tracer For Fatty Acid Imaging."
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden
Marketwired - Mon Oct 20, 7:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented by Dr. Fabian Demeure, an author of the abstract, at the session: Cardiovascular System: Cardiac PET Imaging on October 19th at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.
